Consensus and modeling guidance
Modeling guidance
Clariant targets a Capex spend of ~ CHF 150 - 200 million Swiss francs in 2026.
Clariant targets to defend a solid investment rating.
Clariant targets to create value for shareholders by achieving above-average returns and distributing a stable or rising dividend.
CHF 59 m of CHF 80 m targeted cost savings achieved as of end of Q1 2026; remainder expected in 2026.
Divestments and closures create a negative top-line impact of 1 % ( Group) and 2 % (Care Chemicals) to 2026 sales.
For FY 2026, Clariant expects 3 - 5 % headwind on sales.
As of Q1 2026, Clariant expects
- raw material cost to go mid- to high single-digit percent up,
- energy costs to go mid- to high single-digit percent up, and
- logistic cost to go double-digit percent up.
As of Q1 2026, Clariant expects challenging market conditions with increased macroeconomic challenges, uncertainties and risks for the full year 2026.
The conflict in the Middle East will continue to negatively impact customer demand in the Catalysts and Oil Services (Care Chemicals) businesses, and result in an inflationary raw material, energy and logistic costs environment. To mitigate these cost increases, Clariant activated its proven value-based price management, further supported by a continued focus on active cost initiatives in a challenging demand environment.
Clariant therefore continues to expect sales in local currency to be around flat as it looks to offset a negative top-line impact for the Group of 1 % (2 % in Care Chemicals) from its portfolio pruning in the prior year. Growth is expected in Adsorbents & Additives with slight underlying growth in Care Chemicals, while sales in Catalysts are now expected to be below the levels of 2025.
Clariant expects an EBITDA margin before exceptional items of around 18 % in 2026.
For FY 2026, Clariant assumes a tax rate of 27 - 29 % due to the earnings distribution globally.
Consensus
Disclaimer: Consensus earnings estimates are based on earnings projections made by equity analysts who cover Clariant. Any opinions, forecasts, estimates, projections or predictions regarding Clariant’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Clariant or its management. Clariant does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. Clariant assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.
Contact us
Clariant’s Investor Relations team is committed to an open and fair dialogue with all of its stakeholders. Please contact us.
